4D Molecular Therapeutics, Inc. (FDMT): Cash & Equivalents
$60.24M
As of 2025-12-31
$70.37M
As of 2026-06-30
+4.8%
3-year compound annual growth
-26.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $60.24M | -59.7% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $149.34M | -40.1% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $249.11M | +375.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $52.35M | -65.8% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $153.00M | -44.7% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $276.73M | +457.3% | 2022-03-28, Balance as of period end |
| 2019-12-31 | $49.65M | n/a | 2021-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $743.29M | +25.1% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
Compare FDMT, MGTX, AUTL, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗